Jefferies assumed coverage of U.S. Physical Therapy (USPH) with a Buy rating and a price target of $102, down from $110. As the company pursues strategic hospital alliances and faces a more favorable pricing environment with improved Medicare rates, the firm sees organic growth acceleration and margin expansion, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USPH:
- U.S. Physical Therapy Lifts Outlook After Record Q2
- US Physical Therapy Posts Strong 2025 Results, Outlines 2026 Strategy
- US Physical Therapy Posts Strong 2025 Results, Raises Dividend
- Buy Rating on Reaccelerating Growth and Earnings Upside from New Hospital Alliances
- U.S. Physical Therapy reports Q4 non-GAAP EPS 67c, consensus 67c